Humacyte (HUMAW) Stock Analysis

What Humacyte does

Humacyte, Inc. is a company dedicated to the creation and production of bioengineered human tissues that are readily available and suitable for implantation. These advanced tissues are intended for the treatment of a variety of diseases and medical conditions, applicable to numerous anatomical sites and therapeutic areas. The company employs its distinct, proprietary scientific platform to engineer and manufacture human acellular vessels (HAVs). A significant advantage of these HAVs is their capacity to be implanted into patients without triggering an adverse immune response or leading to rejection by the body. Humacyte is actively developing a diverse portfolio of HAVs, aiming to address needs within the vascular repair, reconstruction, and replacement market. This encompasses uses in cases of vascular trauma, establishing arteriovenous access for hemodialysis, treating peripheral arterial disease, performing pediatric heart surgery, and executing coronary artery bypass grafting. Additionally, their technology supports the delivery of cellular therapies, such as pancreatic islet cell transplantation for managing Type 1 diabetes. Established in 2004, Humacyte, Inc. is headquartered in Durham, North Carolina.

Key metrics

ETFs linked to HUMAW

Broad-market and Healthcare sector ETFs an investor holding Humacyte is often also exposed to. Open an ETF page to see its actual top holdings.

PortView Portfolio Insights

PortView analyzes how HUMAW fits your actual portfolio — position weight, portfolio concentration, unrealized gain/loss, contribution to return, sector exposure, indirect exposure through the ETFs you hold, and correlation with your other holdings. Connect a portfolio to see your personalized figures; PortView never shows another user's private holdings.

Similar companies

Frequently asked questions

What is the ticker symbol for Humacyte?

Humacyte trades under the ticker HUMAW on NASDAQ.

Which exchange is HUMAW listed on?

HUMAW is listed on NASDAQ.

What sector does Humacyte operate in?

Humacyte is classified in the Healthcare sector (Biotechnology industry).

How can PortView help analyze HUMAW in a portfolio?

PortView shows HUMAW's weight in your portfolio, its contribution to return and risk, sector exposure, indirect exposure through ETFs you own, and correlation with your other holdings.